scholarly journals Insulin‐GLP‐1 receptor agonist relay and GLP‐1 receptor agonist first regimens in individuals with type 2 diabetes: a randomized, open‐label trial study

2022 ◽  
Author(s):  
Yumie Takeshita ◽  
Yuki Kita ◽  
Takeo Tanaka ◽  
Hisanori Goto ◽  
Yujiro Nakano ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Open Label ◽  
Open Label Trial

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

The Lancet ◽  
2009 ◽  
Vol 373 (9681) ◽  
pp. 2125-2135 ◽  
Author(s):  
Philip D Home ◽  
Stuart J Pocock ◽  
Henning Beck-Nielsen ◽  
Paula S Curtis ◽  
Ramon Gomis ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Cardiovascular Outcomes ◽  
Oral Agent ◽  
Open Label ◽  
Open Label Trial

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

The Lancet ◽  
2009 ◽  
Vol 374 (9683) ◽  
pp. 39-47 ◽  
Author(s):  
John B Buse ◽  
Julio Rosenstock ◽  
Giorgio Sesti ◽  
Wolfgang E Schmidt ◽  
Eduard Montanya ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Open Label ◽  
Parallel Group ◽  
Open Label Trial

scholarly journals Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study

2018 ◽  
Vol 9 (4) ◽  
pp. 1549-1567 ◽  
Author(s):  
Hisamitsu Ishihara ◽  
Susumu Yamaguchi ◽  
Ikko Nakao ◽  
Taishi Sakatani
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Japanese Patients ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document